Key Takeaways IDEXX shares surged 52.9% YTD, outpacing the industry decline and the benchmark's gains.IDXX's CAG Diagnostics recurring revenues rose 7.5% organically in Q2, with instrument sales up 62%.IDEXX's international growth lifted recurring CAG revenues by 11%, aided by software demand and new users.IDEXX Laboratories (IDXX) has shown remarkable momentum so far this year, climbing 52.9%. The stock has comfortably surpassed the industry’s 12.9% fall and the S&P 500 Composite’s 13.8% gain.Carrying a Za ...